#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Crigler-Najjar syndrome Liposarcoma metastatic Richter's syndrome B-cell small lymphocytic lymphoma Juvenile chronic myelomonocytic leukaemia Small cell lung cancer limited stage Extra-osseous Ewing's sarcoma recurrent Autoimmune disorder Biliary neoplasm Atopic keratoconjunctivitis Cytokine release syndrome Leukodystrophy Small cell lung cancer recurrent Transient ischaemic attack Rhabdoid tumour More trials…

    Learn about Rare Diseases

    Cystic fibrosis – Treatment Gaucher’s disease type III – Basic Information Retinitis pigmentosa – Treatment Wiskott-Aldrich syndrome – Diagnostics IgA nephropathy – Life with Disease Progressive supranuclear palsy – Treatment Pleomorphic leiomyosarcoma – Treatment Mantle cell lymphoma stage IV – Life with Disease Ewing’s sarcoma – Treatment Hereditary hypophosphataemic rickets – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Eight Treg Zalunfiban Azelastine Hydrochloride Estradiol Ponatinib Natalizumab Sodium Fluoride (18F) Riociguat Clebopride Hydrogen Maleate Aluminium Oxide, Hydrated Somatropin Migalastat Metoprolol Emibetuzumab Deucrictibant Rbl016.2 Dydrogesterone Fexofenadine Hydrochloride Eo2317 Nivolumab More therapies…

    Learn about Your Condition

    Peripheral ischaemia Renal cell carcinoma stage IV Diabetic nephropathy Acute on chronic liver failure Acute respiratory failure Tumour thrombosis Acute myocardial infarction Varices oesophageal Staphylococcal bacteraemia Pneumonia Pancreatic carcinoma stage IV Diabetes insipidus Alpha-1 antitrypsin deficiency Cold type haemolytic anaemia Oral neoplasm More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

HER2 positive gastric cancer

  • Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive gastric cancer
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Fluorouracil
    Austria Belgium France Germany Hungary Italy +3

  • Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Fluorouracil
    Austria Belgium Czechia France Germany Italy +6

  • Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

    Recruiting

    3 1 1
    Investigated Diseases:
    • HER2 positive gastric cancer
    • Breast cancer metastatic
    • Colorectal cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    Belgium France Italy Spain

  • Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Gastrooesophageal cancer
    • HER2 positive gastric cancer
    Investigated Drugs:
    • Calcium Folinate Pentahydrate
    • Fluorouracil
    • Oxaliplatin
    Austria Germany

  • Study of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Disodium Folinate
    • Docetaxel
    • Fluorouracil
    Germany

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!